Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

Point-of-care blood device for fast and reliable prediction of drug response in non- small-cell lung carcinoma patients from blood samples

Objective

Chemotherapy is the standard care for the treatment of non-small cell lung carcinoma (NSCLC) patients, however most of non-small cell lung cancer tumours are not sensitive to this treatment. As an alternative to chemoterapy, target therapy with gefitinib (epidermal growth factor receptor-tyrosine kinase inhibitor) has been used in clinical practice in patients with tumours harbouring mutations in EGFR gene, improving their treatment effectiveness. For that reason EGFR mutations analysis should be perform to support the treatment decision for a patient with NSCLC. Despite all the foreseen benefits of EGFR genotyping, the current PCR-based methods used have been shown some associated bottlenecks: i) use of complex samples (tumour biopsy embedded in Formalin Fixed Paraffin, FFPE), ii) require a better understanding from the clinical geneticist to accurately interpret the information provided and to setup the best line of therapy and treatment and iii) the assays are quite expensive and time-consuming. New age diagnostic tools, such as microfluidic platforms and nanodiagnostics are emerging technologies for DNA analysis requiring lower sample volumes and providing comparable sensitivity and specificity at lower costs. Nonetheless, sample preparation and detection of the result of a chemical analysis on-chip are still weak points in many lab-on-a-chip devices. The current proposal, aiming the integration of “all laboratory-based process steps” in one single step, is both challenging and feasible: development of a microfluidic chip that combines blood sample processing (DNA extraction/purification, multiplex amplification) and detection of EGFR mutations in tumour DNA by means of gold and silver-nanoparticles (Ag and Au-nanoprobes). Furthermore a microfluidic chip analyser with an integrated user-friendly software to report genotyping results will be developed.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-SME-2012
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

BSG-SME - Research for SMEs

Coordinator

STAB VIDA INVESTIGACAO E SERVICOS EM CIENCIAS BIOLOGICAS LDA
EU contribution
€ 301 782,00
Address
RUA DOS INVENTORES S/N EDIFICIO MADAN PARQUE SALAS 2.18 E 2.19
2825 182 CAPARICA
Portugal

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (6)

My booklet 0 0